AO Ordine Mauriziano di Torino - Sindromi mielodisplastiche

AG946-C-002

A Phase 2a/2b, Open-label, Proof of Concept (Phase 2a) and Double-blind, Randomized,Placebo-Controlled (Phase 2b), Multicenter, Efficacy, and Safety Study of AG-946 in Participants With Anemia Due to Lower-Risk Myelodysplastic Syndromes ( drug AG948)

CA056-025

A Phase 3, Open-label, Randomized Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) vs Epoetin Alfa for the Treatment of Anemia Due to Revised International Prognostic Scoring System (IPSS-R) Very Low, Low, or Intermediate Risk Myelodysplastic Syndrome (MDS) in Erythropoietin-stimulating Agent (ESA)-naive Participants who are Non-Transfusion Dependent (NTD)  (drug luspatercept)

CA056-1060

Phase 3b, open label study evaluating the efficacy and safety of luspatercept (BMS-986346/ACE-536) initiated at maximunx approved dose in LR-MDS with IPSS-R very low, low or intermediate risk who require RBC transfusion

SY-1425-301

A Randomized, Double-blind, Placebo-controlled Phase 3 Study of SY-1425 plus Azacitidine Versus Placebo Plus Azacitidine in Newly Diagnosed, RARA-positive Adult Patients with Higher-risk Myelodysplastic Syndrome (drug Tamobaritene)